IRX5183 is an orally available, third generation retinoid, first in class RARα agonist. IRX5183 is expected to be safer and more effective than earlier generation retinoids.

IRX5183 was safe and well tolerated in a Phase I/II clinical study in cancer patients. Io Therapeutics is planning additional studies of IRX5183 as a treatment for cancer indications.